CRVL

LLM Evaluations

Transcript Summary

CorVel Corporation reported strong fiscal year 2026 results, with annual revenue reaching $959 million, a 7% increase, and EPS rising 17% to $2.14. The company's performance was driven by the Network Solutions segment, particularly CERIS, which is successfully transitioning to proactive, prepaid solutions that offer faster revenue realization. Patient Management saw steady growth as CorVel continues to invest in its "CorVel Connected" platform, utilizing AI and automation to manage complex claims and mitigate medical inflation. A significant 56% surge in new bookings and a 20% rise in RFP activity during the final quarter indicate accelerating commercial momentum. CorVel's strategic focus on integrating clinical expertise with advanced technology addresses the shifting market demand for outcome-based claims management. The company maintains a fortress balance sheet with $233 million in cash and no debt, facilitating a robust share repurchase program that has retired 69% of outstanding shares since inception. While facing headwinds like rising claim severity and cybersecurity threats, CorVel's management remains confident in its ability to leverage its unified platform for scalable growth. The transition toward shorter-cycle revenue streams and AI-driven operational efficiency positions the company well for the upcoming fiscal year.

5-year share-count history (top 10 holders by peak, incl. exited) + price

Revenue Segments

Filing Risk Scores

CorVel Corporation: Aggressive Accounting and Earnings Smoothing through Allowance Manipulations

Full Earnings Call Transcript — Q4 • 2026-05-20

Operator: Greetings, and welcome to the CorVel quarterly earnings report. [Operator Instructions] As a reminder this conference is being recorded [Operator Instructions] It's now my pleasure to turn the call over to President and CEO, Michael Combs. Please go ahead, sir.
Michael Combs: Thank you. Good morning. Thank you for joining us to review CorVel's March quarter and fiscal year results. Brian Nichols, CorVel's Chief Financial Officer, is on the call with me today. Today I will review business performance, the current environment and market trends and progress on product and service offerings. So let's start with Brian providing an overview of the March quarter and fiscal year results. Brian?
Brian Nichols: Thank you, Michael, and good morning, everyone. The March quarter revenues were $249 million, an increase of 7% compared to $232 million in the March 2025 quarter. Earnings per share for the quarter ended March 31, 2026 were $0.61, up from $0.51 in the same period of the previous year. . For the fiscal year 2026, revenues were $959 million, up 7% from $896 million in the prior fiscal year, and earnings per share was $2.14, an increase of 17% compared to $1.83 for the fiscal year ended March 31, 2025. The effective tax rate increased compared to the prior year, which included a discrete benefit from stock option exercises that did not recur at similar levels. For the fiscal year, Network Solutions delivered strong results with double-digit revenue and profit growth driven by continued momentum across its offerings and solid execution in both property and casualty and commercial health. Results within Network Solutions included the impact of certain onetime events primarily within CERIS, which contributed in part to elevated revenue and profit during the period and added $0.02 of earnings per share. This performance was driven by accelerated post-payment recoveries associated with large payer engagement reflecting a timing-related benefit. Importantly, this engagement, along with these additional large payer wins, is expected to contribute to ongoing revenue and profit tailwinds as these programs scale and mature. Patient management generated low single-digit revenue and profit growth, reflecting a stable demand environment and consistent focus on operational efficiency. The company is making targeted investments to enhance service quality and consistency as a key differentiator, while advancing systems and technology to support more scalable delivery. Personnel levels increased during the period to support service delivery and implementation activity reflecting near-term execution priorities. These levels are expected to normalize as deployments mature and as automation and AI-enabled workflow enhancements are deployed through the remainder of the year and into 2027, the company expects to realize sustained productivity gains, reduce reliance on manual processes and further improve operating leverage. Overall, the company's balanced portfolio positions us to deliver scalable growth through network solutions while driving increased differentiation and future growth in patient management through ongoing technology and AI-enabled investments. New bookings in the March quarter increased 56% year-over-year. reflecting high demand and accelerating commercial momentum across the business. RFP activity rose 20% over the same period, supporting steady pipeline expansion. Importantly, these bookings primarily multiyear are expected to contribute meaningfully to revenue and profit growth in the back half of the calendar year as implementation scale.
Michael Combs: Thank you, Brian. Now transitioning to market trends. Health care payers are operating in an increasingly complex environment with rising administrative costs, growing claim complexity and continued pressure to improve financial and clinical outcomes. In response, the market is shifting away from reactive correction towards more proactive models of payment accuracy and cost management. CERIS is well aligned with this shift. Our platform spans both prepay and postpaid solutions, allowing us to improve accuracy earlier in the claims life cycle, while maintaining strong recovery capabilities where needed. This integrated approach enables our customers to reduce downstream work, lower administrative burden and strengthen provider partnerships. We are seeing increasing demand for these capabilities. In 2026, we are launching 4 large payer programs, including 2 new multiyear partnerships with top 10 national payers. These enterprise scale implementations reinforce the strength of our value proposition and will contribute meaningfully to revenue and profit growth as they mature. The industry also continues to move upstream with prepayment accuracy becoming an increasingly important strategic priority for payers. CERIS is advancing this transition by expanding prepaid solutions and migrating services historically performed postpaid in more proactive workflows. This evolution supports a more predictable and scalable revenue model while delivering earlier intervention and improved operational efficiency for our customers. Looking ahead, we see a healthy and growing pipeline as customers prioritize cost containment, payment accuracy and operational efficiency. Supported by long-term contracts and expanding adoption of prepaid solutions, we are influencing a shift towards revenue streams with a shorter realization cycle, typically 1 to 2 months for prepaid compared to 6 months or longer for postpaid, while maintaining comparable margin profiles. Combined with intentional investment technology, CERIS is well positioned to deliver sustained scalable growth over time. The technology is a key enabler of this strategy. Our ongoing investment in AI and automation to enhance accuracy, increase throughput and reduce reliance on manual processes. Importantly, our approach focuses on augmenting our teams, providing actionable insights, improving decision-making and enabling clinical and operational professionals to focus on higher-value work. This combination of technology and domain expertise is a meaningful differentiator and supports both scalability and consistency in outcomes. The workers' compensation and risk management environment continues to evolve in meaningful ways. Across the industry, we are seeing rising claims severity, increased medical costs and greater complexity driven by an aging workforce, increased comorbidities and expanded behavioral health considerations. At the same time, our partners are navigating provider access constraints, regulatory complexity and ongoing pressure to improve outcomes while controlling costs. These dynamics are accelerating a broader shift in the market from transactional cost management towards integrated, outcome-focused claims management supported by real-time data, automation and clinical insights. At CorVel, we have aligned our strategy and investments to meet this moment. We are advancing CorVel's connected interface within our platform, which brings together artificial intelligence, real-time data integration and embedded clinical and claims expertise into a unified operating model. This platform enables earlier risk identification, faster access to care and more informed decision support throughout the claim continuum. By focusing our use of artificial intelligence on amplifying the work of our teams through workflow automation, predictive insights and next best action guidance, we enable claims and clinical professionals to focus on the most complex and impactful aspects of care. This approach improves outcomes while increasing scalability and productivity in an environment where labor constraints remain a challenge. One of the key differentiators is the integration of our platform. Rather than operating as a collection of point solutions, CorVel Connected brings together claims clinical pharmacy and network data in real time. This creates continuous feedback across the life cycle of a claim and supports more consistent outcome-driven decision-making. In effect, we are rearchitecting the claims process around actionable intelligence rather than administrative workflow. We are also addressing cost pressures, particularly in medical and slurry and pharmacy spend through clinically driven utilization management, expanded telemedicine capabilities and the development of bundled and episode-based care models. These initiatives are designed to improve both access and quality of care while maintaining appropriate cost control. At the same time, we are investing in automation, API-driven connectivity and compliance infrastructure to reduce friction, ensure regulatory alignment and enable real-time exchange data across the ecosystem and with our partners, Taken together, these efforts reflect a consistent strategy to move beyond traditional claims administration and deliver a technology-enabled, clinically integrated model focused on total claims outcomes. CorVel is well positioned not only to navigate the current environment but also to gain market share as partners increasingly prioritize scalable, intelligent platforms that deliver both clinical and financial results with greater consistency and transparency. As we further advance automation and AI-enabled capabilities across our platform, the broader operating environment is also evolving rapidly. The increasing sophistication and speed of AI-driven vulnerability discovery and exploitation are reshaping cybersecurity and operational risk dynamics across the industry. In response, management is further enhancing governance framework, strengthening controls and investing in resilience initiatives designed to support more proactive risk identification and mitigation. These efforts align with growing customer demand for solutions that are adaptive, auditable and durable under heightened operational and regulatory scrutiny. Brian, would you now provide additional texture on the financial results?
Brian Nichols: Certainly, Michael, CorVel's net income for fiscal year 2026 is $110 million. nearly a 14% increase over fiscal year 2025 at $95 million. The fourth quarter contributed $31 million to this year's income total, which is $5 million higher than the same quarter of fiscal year 2025. While the increase in our effective tax rate did temper growth to earnings, much of that increase was offset by business growth among various network solutions products referenced earlier, along with the reduced general and administrative costs. During the fourth quarter, general and administrative expenses decreased by $1.3 million compared to the same quarter of fiscal year 2025, bringing G&A down from 10.6% of revenue to 9.4%. CorVel's operating margin for the fiscal year 2026 was 15%, which was an improvement of 1.4% over 2025. During the 2026 fiscal year, CorVel repurchased 872,744 shares at a cost of $56 million. 366,306 of the shares were repurchased during the fourth quarter at a cost of $20 million. From inception to date, the company has repurchased 115.3 million shares for an aggregated total of $868 million. Through this program, the company has now repurchased 69% of total shares outstanding at an average price of $7.70 per share. The repurchasing of shares continues to be funded from the company's strong operating cash flow. CorVel's day sales outstanding was 37 days in the March 2026 quarter, which is an improvement of 4 days compared to the same period of the previous year. At fiscal year-end, the cash balance was $233 million. Free cash flow was $66 million, which is $7 million increase compared to fiscal year 2025. CorVel's robust and debt-free balance sheet uniquely positions us for accelerating strategic product expansion, technological advancement and acquisition opportunities. Our fiscal strategy remains committed to responsible management of financial risks to protect our agility for investing in development. Thank you for your time this morning. I will now invite the operator to open the session for questions.
Operator: [Operator Instructions]
Unknown Executive: Thank you so much, Kevin. We're going to go ahead and return the call to the operator.
Operator: Thank you. There are no questions at this time. Ladies and gentlemen, that does conclude today's teleconference and webcast.